Aktuelle investeringer
3044 Investeringer
Titel Sortér faldende | Periode | Region | Program |
---|---|---|---|
3DP Biomedical Device | 2016 - 2018 | Region Hovedstaden | Innobooster
|
3DP Biomedical Device
Periode
2016 - 2018
Region
Region Hovedstaden Program
Innobooster Fagområde
Biotek, Medico og Sundhed Investering
Percentage
29.89 Fondens investering
444.000 Samlet budget
1,5 mio. Projektdeltagere
Ferrosan Medical Devices A/S Projektleder
Hjemmeside
| |||
4. generations softdrink produktion | 2019 - 2020 | Region Syddanmark | Innobooster
|
4. generations softdrink produktion
Periode
2019 - 2020
Region
Region Syddanmark Program
Innobooster Fagområde
Produktion, Materialer, Digitalisering og IKT Investering
Percentage
23.26 Fondens investering
2,7 mio. Samlet budget
11,5 mio. I projektet udvikles en hybrid pasteuriseringsløsning og robotgribeløsning, der muliggør en hurtig og fleksibel tappeløsning til drikkevarer uden egenkonservering og med komplekse proteinstrenge. Løsningen vil kunne levere samme renhed som langt dyrere og langsommere autoklaveløsninger, samt en avanceret sensorpakke der muliggør automatiseret dokumentation af alle delprocesser i produktionen. Løsningen vil også muliggøre rentabel produktion af selv meget små højkvalitetsproduktserier.
Projektdeltagere
Vestfyen A/S Bryggeriet Projektleder
Hjemmeside
| |||
4Mvideo IV | 2018 - 2019 | Region Hovedstaden | Innobooster
|
4Mvideo IV
Periode
2018 - 2019
Region
Region Hovedstaden Program
Innobooster Fagområde
Biotek, Medico og Sundhed Investering
Percentage
33 Fondens investering
207.900 Samlet budget
630.000 Daglig motion er vigtig når man kommer op i alderen. 30 minutter daglig motion øger chancen for et længere liv med højere livskvalitet – men mange følger ikke anbefalingerne. 4Mvideo er et videobaseret cykelmotionssystem til seniorer (se film www.4mvideo.dk), som øger motivation og muligheder for motion. Det består af et website med cykelvideoer og en 4Mvideo-app, der installeret på en tablet-computer, kan afspille cykelvideoer i takt med pedaltrådet på motionscykel med påmonteret kadancesensor.
Projektdeltagere
4Mvideo IVS Projektleder
Hjemmeside
| |||
692482 EnSO | 2016 - 2019 | Region Hovedstaden | International Collaborations
|
692482 EnSO
Periode
2016 - 2019
Region
Region Hovedstaden Program
International Collaborations Fagområde
Produktion, Materialer, Digitalisering og IKT Investering
Percentage
0 Fondens investering
1,6 mio. Samlet budget
0 Projektdeltagere
GN RESOUND A/S Projektleder
Hjemmeside
| |||
90452 NorDCaP - Aarhus University Hospital | 2019 - 2021 | Region Midtjylland |
|
90452 NorDCaP - Aarhus University Hospital
Periode
2019 - 2021
Region
Region Midtjylland Program
Fagområde
Biotek, Medico og Sundhed Investering
Percentage
0 Fondens investering
4,8 mio. Samlet budget
0 Today, when a fetal malformation is detected during pregnancy, current technologies offer an explanation in less than one in five cases. This means that couples may decide to terminate or continue a pregnancy without knowing if the malformation is a symptom of a multi-organ syndrome, a treatable disease or a single malformation. Furthermore, in on-going pregnancies, the prenatal surveillance, delivery, and post-natal treatment and care are carried out without knowing the specific diagnosis/prognosis of the child, which often leads to over- or under-treatment of the child, failed or ineffective therapeutic interventions, parental anxiety and feelings of guilt, as well as uncertainty and frustration amongst health professionals.
We propose personalised medicine for the unborn child and family by implementing the newest genetic technologies - Whole Exome Sequencing and Whole Genome Sequencing - as a first line diagnostic tool for all fetal malformations that are currently unexplained.
Projektdeltagere
Aarhus University Hospital, Stavanger University Hospital, Mehiläinen, Karolinska Institute, OncoAlgorithms AB, ThermoFisher Scientific, Defactum Projektleder
Hjemmeside
| |||
90452 NorDCaP - DEFACTUM | 2019 - 2021 | Region Midtjylland |
|
90452 NorDCaP - DEFACTUM
Periode
2019 - 2021
Region
Region Midtjylland Program
Fagområde
Biotek, Medico og Sundhed Investering
Percentage
0 Fondens investering
773.065 Samlet budget
0 Today, when a fetal malformation is detected during pregnancy, current technologies offer an explanation in less than 1 in 5 cases. This means that couples may decide to terminate or continue a pregnancy without knowing if the malformation is a symptom of a multi-organ syndrome, a treatable disease or a single malformation. Furthermore, in on-going pregnancies, the prenatal surveillance, delivery, and post-natal treatment and care are carried out without knowing the specific diagnosis/prognosis of the child, which often leads to over- or under-treatment of the child, failed or ineffective therapeutic interventions, parental anxiety and feelings of guilt, as well as uncertainty and frustration amongst health professionals.
We propose personalised medicine for the unborn child and family by implementing the newest genetic technologies - Whole Exome Sequencing and Whole Genome Sequencing - as a first line diagnostic tool for all fetal malformations that are currently unexplained.
Projektdeltagere
Aarhus University Hospital, Stavanger University Hospital, Mehiläinen, Karolinska Institute, OncoAlgorithms AB, ThermoFisher Scientific, Defactum Projektleder
Hjemmeside
| |||
90569 NORD-TREAT - University Hospital of Southern Jutland | 2019 - 2023 | Region Syddanmark |
|
90569 NORD-TREAT - University Hospital of Southern Jutland
Periode
2019 - 2023
Region
Region Syddanmark Program
Fagområde
Biotek, Medico og Sundhed Investering
Percentage
0 Fondens investering
2,5 mio. Samlet budget
0 The NORDTREAT project will build on the achievements within recent large-scale European initiatives that includes cross-disciplinary collaborations between academia, hospitals, biomedical companies and patient organisations. The overall aim is to improve Inflammatory bowel disease (IBD) patients' prognosis and quality of life by introducing a novel personalized medicine algorithm that is based on recently generated -omics data.
IBD is a disease entity of unknown origin, characterized by a chronic inflammation in the gastrointestinal tract. IBD is increasing, especially among teenagers, and today 0.5-1% of the Nordic population is affected. The disease course varies from an indolent course to an aggressive, treatment refractory disease, with need of repeated hospital admissions, surgery and increased risk of comorbidity including cancer. Thus, IBD have severe consequences for many affected individuals, including life-long medication, hospitalizations, recurring sick-leaves, and surgic
Projektdeltagere
Odense University Hospital, Örebro University, Oslo University Hospital, University of Oslo, University Hospital of Southern Jutland, Nordic Bioscience A/S, The National University Hospital of Iceland, Linköping University Projektleder
Hjemmeside
| |||
90569 - NORD-TREAT - Nordic Bioscience A/S | 2019 - 2023 | Region Hovedstaden |
|
90569 - NORD-TREAT - Nordic Bioscience A/S
Periode
2019 - 2023
Region
Region Hovedstaden Program
Fagområde
Biotek, Medico og Sundhed Investering
Percentage
0 Fondens investering
309.300 Samlet budget
0 The NORDTREAT project will build on the achievements within recent large-scale European initiatives that
includes cross-disciplinary collaborations between academia, hospitals, biomedical companies and patient
organisations. The overall aim is to improve Inflammatory bowel disease (IBD) patients' prognosis and
quality of life by introducing a novel personalized medicine algorithm that is based on recently generated
-omics data.
In this project, our aim is to selectively identify patients with a poor prognosis based on a novel objective protein signature, recently identified by members of the NORDTREAT team, and adapt the treatment in these patients to minimize disease-induced damage on the gastrointestinal tract and to improve longterm disease outcomes. NORDTREAT exploitation plan includes the development of this protein signature into a diagnostic application, implementation of this diagnostic application as a prognostic tool in healthcare and exploration of potential biomarkers.
Projektdeltagere
Odense University Hospital, Örebro University, Oslo University Hospital, University of Oslo, University Hospital of Southern Jutland, Nordic Bioscience A/S, The National University Hospital of Iceland, Linköping University Projektleder
Hjemmeside
| |||
90569 NORD-TREAT - Odense University Hospital, Department of Medical Gastroenterology | 2019 - 2023 | Region Syddanmark |
|
90569 NORD-TREAT - Odense University Hospital, Department of Medical Gastroenterology
Periode
2019 - 2023
Region
Region Syddanmark Program
Fagområde
Biotek, Medico og Sundhed Investering
Percentage
0 Fondens investering
2,0 mio. Samlet budget
0 The NORDTREAT project will build on the achievements within recent large-scale
European initiatives that includes cross-disciplinary collaborations between
academia, hospitals, biomedical companies and patient organisations. The overall
aim is to improve Inflammatory bowel disease (IBD) patients' prognosis and quality
of life by introducing a novel personalized medicine algorithm that is based on
recently generated -omics data.
IBD is a disease entity of unknown origin, characterized by a chronic inflammation
in the gastrointestinal tract. IBD is increasing, especially among teenagers, and
today 0.5-1% of the Nordic population is affected. The disease course varies from
an indolent course to an aggressive, treatment refractory disease, with need of
repeated hospital admissions, surgery and increased risk of comorbidity including
cancer. Thus, IBD have severe consequences for many affected individuals,
including life-long medication, hospitalizations, recurring sick-leaves,
Projektdeltagere
Odense University Hospital, Örebro University, Oslo University Hospital, University of Oslo, University Hospital of Southern Jutland, Nordic Bioscience A/S, The National University Hospital of Iceland, Linköping University Projektleder
Hjemmeside
| |||
90580 PM-Heart - Copenhagen University Hospital, Rigshospitalet | 2019 - 2023 | Region Hovedstaden |
|
90580 PM-Heart - Copenhagen University Hospital, Rigshospitalet
Periode
2019 - 2023
Region
Region Hovedstaden Program
Fagområde
Biotek, Medico og Sundhed Investering
Percentage
0 Fondens investering
5,9 mio. Samlet budget
0 Globally, the leading cause of years of life lost is ischemic heart disease (IHD). IHD causes chest pain, myocardial infarcts, reduced physical capacity and reduces lifeexpectance. Many disease mechanisms and risk factors are known in IHD, but we need approaches to manage complex data that can drive precise sub-classifications and risk stratification rather than continuing present “one-size-fits-all” regimes, which in many cases is an inefficient, costly, potentially harmful over-management. At the
same time, patients at high risk may not be identified. The objective is to develop and clinically implement personalized medicine (PM) in IHD to avoid overtreatment as well as undertreatment. This will be achieved by a Nordic interdisciplinary collaboration by merging large cohorts with well-described
IHD geno- and phenotype data; clinical data, Nordic national registry data, genetics, socio-economics, trajectories of co-morbidities, medications etc into The Heart IHD Algorithm.
Projektdeltagere
Danish National Genome Center, KU, Norwegian University of Science and Technology, Oslo University Hospital Projektleder
Hjemmeside
| |||
90580 PM-Heart - Copenhagen University Hospital, Rigshospitalet | 2019 - 2023 | Region Hovedstaden |
|
90580 PM-Heart - Copenhagen University Hospital, Rigshospitalet
Periode
2019 - 2023
Region
Region Hovedstaden Program
Fagområde
Biotek, Medico og Sundhed Investering
Percentage
0 Fondens investering
6,4 mio. Samlet budget
0 Globally, the leading cause of years of life lost is ischemic heart disease (IHD). IHD causes chest pain, myocardial infarcts, reduced physical capacity and reduces life-expectance.
Many disease mechanisms and risk factors are known in IHD, but we urgently need approaches to manage complex data that can drive precise sub-classifications and risk stratification rather than continuing present “one-size-fits-all” regimes, which in many cases is an inefficient, costly, potentially harmful over-management. At the same time, patients at high risk may not be identified.
The objective is to develop and clinically implement personalized medicine (PM) in IHD to avoid overtreatment as well as undertreatment. This will be achieved by a Nordic interdisciplinary collaboration by merging large cohorts with well-described IHD geno- and phenotype data; clinical data, Nordic national registry data, genetics, socio-economics, trajectories of co-morbidities, medications etc into The Heart IHD Algorithm
Projektdeltagere
Danish National Genome Center, KU, Norwegian University of Science and Technology, Oslo University Hospital Projektleder
Hjemmeside
| |||
90580 PM-Heart - Danish National Genome Center | 2019 - 2023 | Region Hovedstaden |
|
90580 PM-Heart - Danish National Genome Center
Periode
2019 - 2023
Region
Region Hovedstaden Program
Fagområde
Biotek, Medico og Sundhed Investering
Percentage
0 Fondens investering
1,7 mio. Samlet budget
0 Globally, the leading cause of years of life lost is ischemic heart disease (IHD). IHD causes chest pain, myocardial infarcts, reduced physical capacity and reduces life-expectance.
Many disease mechanisms and risk factors are known in IHD, but we urgently need approaches to manage complex data that can drive precise sub-classifications and risk stratification rather than continuing present “one-size-fits-all” regimes, which in many cases is an inefficient, costly, potentially harmful over-management. At the same time, patients at high risk may not be identified.
The objective is to develop and clinically implement personalized medicine (PM) in IHD to avoid overtreatment as well as undertreatment. This will be achieved by a Nordic interdisciplinary collaboration by merging large cohorts with well-described IHD geno- and phenotype data; clinical data, Nordic national registry data, genetics, socio-economics, trajectories of co-morbidities, medications etc into The Heart IHD Algorithm
Projektdeltagere
Danish National Genome Center, KU, Norwegian University of Science and Technology, Oslo University Hospital Projektleder
Hjemmeside
| |||
90645 PERAID - Rigshospitalet | 2019 - 2023 | Region Hovedstaden |
|
90645 PERAID - Rigshospitalet
Periode
2019 - 2023
Region
Region Hovedstaden Program
Fagområde
Biotek, Medico og Sundhed Investering
Percentage
137.31 Fondens investering
4,3 mio. Samlet budget
3,1 mio. The PERAID project proposes to implement personalized medicine (PM) in severe infectious diseases,
specifically focusing on the life-threatening necrotizing soft tissue infections (NSTI) as well as the large
heterogeneous group of sepsis patients. Personalized medicine is a neglected, albeit much desired,
development in the field of acute infectious diseases. The patient population is highly heterogeneous with different pathogens, pathogenic mechanisms, as well as varying predisposing host factors, and importantly, a dysregulated host response to infection is directly linked to severity and outcome of severe infections, i.e. sepsis and NSTI. PERAID builds on the advances and resources created in the EU FP7-project INFECT, including the worlds largest patient cohort on NSTI (Scandinavian patients enrolled by PERAIDs partners from Denmark, Norway and Sweden), biobank, multi-omics data, and pathophysiologic models.
Projektdeltagere
Rigshospitalet, Karolinska Institute, University of Bergen, St. Olavs Hospital Trondheim Projektleder
Hjemmeside
| |||
90825 NORA - Department of Rheumatology, Rigshospitalet, Glostrup | 2019 - 2022 | Region Hovedstaden |
|
90825 NORA - Department of Rheumatology, Rigshospitalet, Glostrup
Periode
2019 - 2022
Region
Region Hovedstaden Program
Fagområde
Biotek, Medico og Sundhed Investering
Percentage
0 Fondens investering
3,4 mio. Samlet budget
0 Please see upload
Rheumatoid arthritis (RA, life-time risk around 2%) entails a considerable burden for affected individuals
(pain, reduced life-span, reduced function, reduced quality of life), for health-care, and for society (reduced
work ability, and treatment costs that currently accounts for almost 10% of the total drug expenditure).
Delayed or ineffective treatment leads to joint destruction, co-morbidities, and increased mortality.
RA demonstrates a striking heterogeneity in terms of clinical presentation, response to treatment, and
clinical outcomes. Emerging data suggest that RA is not one disease but comprised by subsets with distinct
etiologies, which may explain the difficulties in predicting disease course, treatment response, and long-term
outcomes. So far we treat by tradition and try different treatments in a rather random fashion and often too
late, despite the increasing number of different, and still expensive, medicines that have become available in
rout
Projektdeltagere
ZiteLab ApS, Thermo Fisher Scientific/Phadia AB, Uppsala University, Linköping University, Elsa science, Diakonhjemmet Hospital Projektleder
Hjemmeside
| |||
90825 NORA - ZiteLab ApS | 2019 - 2022 | Region Hovedstaden |
|
90825 NORA - ZiteLab ApS
Periode
2019 - 2022
Region
Region Hovedstaden Program
Fagområde
Biotek, Medico og Sundhed Investering
Percentage
0 Fondens investering
1,2 mio. Samlet budget
0 Rheumatoid arthritis (RA, life-time risk around 2%) entails a considerable burden for affected individuals
(pain, reduced life-span, reduced function, reduced quality of life), for health-care, and for society (reduced
work ability, and treatment costs that currently accounts for almost 10% of the total drug expenditure).
Delayed or ineffective treatment leads to joint destruction, co-morbidities, and increased mortality.
RA demonstrates a striking heterogeneity in terms of clinical presentation, response to treatment, and
clinical outcomes. Emerging data suggest that RA is not one disease but comprised by subsets with distinct
etiologies, which may explain the difficulties in predicting disease course, treatment response, and long-term
outcomes. So far we treat by tradition and try different treatments in a rather random fashion and often too
late, despite the increasing number of different, and still expensive, medicines that have become available in
routine care.
...
Projektdeltagere
ZiteLab ApS, Thermo Fisher Scientific/Phadia AB, Uppsala University, Linköping University, Elsa science, Diakonhjemmet Hospital Projektleder
Hjemmeside
|